B
Bull
Bull · 25%CV
$5.79
Scenario price
$6.990
+0.195 (+2.79%)At close
Loading chart…
- High
- 7.180
- Open
- 6.720
- VWAP
- 6.94
- Volume
- 320.23K
- Mkt Cap
- —
- Low
- 6.660
- Amount
- 2.22M
- EV/EBITDA, TTM
- -8.69
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.
AI analysis of CapsoVision Inc (CV)
BuyCapsoVision Inc is a good buy right now due to its recent FDA clearance for an AI-assisted tool, which could enhance its market position and drive future growth. The current price is $6.53, and analysts have set a price target of $9 to $10, indicating a potential upside of 37% to 53%. Additionally, the company reported a 10% revenue growth in Q2 2026, reflecting strong demand for its products. However, the main risk is its negative net income, which stands at -$7,481,000 for Q2 2026, indicating ongoing financial challenges that investors should consider.
Valuation Metrics
The current forward P/E ratio for CapsoVision Inc (CV) is 0.00, compared to its 5-year average forward P/E of -10.86.
Alphio AI Price Scenarios for CV
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
5.009-28NASDAQ.COMCapsoVision Receives FDA Clearance for AI-Assisted Tool
9.009-28NASDAQ.COMCapsoVision Receives FDA Clearance for AI-Assisted Tool
9.508-14Yahoo FinanceCapsoVision Reports 10% Revenue Growth in Q2 2026
9.508-04NASDAQ.COMCRISPR Therapeutics Reports Narrowed Loss in Q2 2026
5.008-04NASDAQ.COMCapsoVision Launches AI Highlights for Capsule Endoscopy Studies
CV FAQ — answered by Alphio AI
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule. It operates in the Healthcare sector.
CapsoVision Inc is a good buy right now due to its recent FDA clearance for an AI-assisted tool, which could enhance its market position and drive future growth. The current price is $6.53, and analysts have set a price target of $9 to $10, indicating a potential upside of 37% to 53%. Additionally, the company reported a 10% revenue growth in Q2 2026, reflecting strong demand for its products. However, the main risk is its negative net income, which stands at -$7,481,000 for Q2 2026, indicating ongoing financial challenges that investors should consider.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.